Although insulin remains the primary treatment [122], some oral glycemic agents have shown potential neuroprotective benefits beyond glucose control; however, they are not recommended for managing post-stroke hyperglycemia due to the increased risk of hypoglycemia and acidosis in acutely ill patients, particularly in dysphagic stroke patients [108]. This evidence concerns the gene INS and Hypoglycemia.